ATRA - Atara Biotherapeutics, Inc.
NEXT EARNINGS:
May 6, 2026
EPS Est: $-0.33
|
Rev Est: $2.4M
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$15.50
DETAILS
HIGH:
$25.00
LOW:
$6.00
MEDIAN:
$15.50
CONSENSUS:
$15.50
UPSIDE:
210.62%
Market Cap:
40.81M
Volume:
46,934
Avg Volume:
449,109
52 Week Range:
3.92-19.145
Sector:
Healthcare
Industry:
Biotechnology
Beta:
-0.40
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
153
IPO Date:
2014-10-16
EPS (TTM):
3.16
P/E Ratio:
1.58
Revenue (TTM):
120.77M
Total Assets:
20.23M
Total Debt:
52.80M
Cash & Equiv:
8.48M
Rev Growth (5Y):
85.1%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
687.2%
Debt/Equity:
-1.37
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-03-16 | $-0.25 | $-0.09 | -177.8% | $1.6M | $3.4M | -51.2% |
| 2025-11-12 | $-0.32 | $-0.83 | +61.4% | $3.5M | $700000 | +393.3% |
| 2025-08-11 | $0.19 | $-0.32 | +159.4% | $17.6M | $1.8M | +876.4% |
| 2025-05-15 | $3.50 | $-3.07 | +214.0% | $98.1M | $4.3M | +2182.5% |
| 2025-03-07 | $-1.19 | $-3.82 | +68.8% | $32.8M | $20.6M | +59.1% |
| 2024-11-12 | $-2.93 | $-3.77 | +22.3% | $40.2M | $33.1M | +21.4% |
| 2024-08-12 | $-3.10 | $-1.25 | -148.0% | $28.6M | $40.0M | -28.4% |
| 2024-05-09 | $-5.75 | $-9.25 | +37.8% | $27.4M | $24.7M | +10.8% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 32.69M | (85.40M) | (276.13M) | (228.30M) | (340.14M) | (306.62M) | (290.98M) | (2.31B) | (1.19B) | (790.49M) | (572.21M) | (280.06M) |
| EPS | 2.61 | -11.41 | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 |
| Total Assets | 20.23M | 109.10M | 165.50M | 376.42M | 468.13M | 588.12M | 342.94M | 391.84M | 217.78M | 263.91M | 324.98M | 106.12M |
| Total Debt | 52.80M | 43.83M | 57.87M | 71.70M | 28.27M | 15.03M | 15.72M | 738,000 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 8.48M | 25.03M | 25.84M | 92.94M | 106.08M | 200.40M | 74.32M | 60.70M | 79.22M | 47.97M | 23.75M | 21.90M |
| Operating Cash Flow | (50.94M) | (68.72M) | (192.98M) | (270.43M) | (220.52M) | (180.76M) | (235.63M) | (179.77M) | (87.50M) | (60.02M) | (37.16M) | (16.63M) |
| Free Cash Flow | (50.94M) | (68.96M) | (194.20M) | (274.62M) | (231.10M) | (185.27M) | (241.36M) | (215.70M) | (107.73M) | (63.05M) | (37.45M) | (16.67M) |
| FCF per Share | -4.06 | -9.21 | -45.84 | -67.32 | -61.68 | -62.61 | -117.60 | -123.08 | -90.19 | -54.86 | -36.59 | -83.60 |
| Book Value | (38.50M) | (97.28M) | (99.23M) | 126.64M | 279.61M | 462.34M | 290.78M | 338.86M | 177.86M | 253.74M | 315.10M | 103.18M |
| Cash & ST Investments | 8.48M | 42.50M | 51.73M | 242.82M | 371.07M | 500.66M | 259.11M | 309.63M | 166.10M | 255.68M | 320.48M | 104.12M |
| Return on Equity | N/A | N/A | N/A | -1.80 | -1.22 | -0.66 | -1.00 | -6.81 | -6.72 | -3.12 | -1.82 | -2.71 |